FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
This article was originally published in The Tan Sheet
Executive Summary
Released on the heels of the over-the-counter approval of the weight loss drug orlistat as GlaxoSmithKline's alli, FDA's draft guidance on obesity product development increases the agency's emphasis on lifestyle modification as an alternative to and context for drug therapy